期刊
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
卷 362, 期 2, 页码 113-121出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjms.2021.03.004
关键词
Abdominal pain; Delta-aminolevulinic acid; Heme; Porphobilinogen; Porphyrias
资金
- Alnylam Pharmaceuticals, Cambridge, MA, USA
- Alnylam Pharmaceuticals
Acute hepatic porphyria (AHP) is a rare metabolic disease that can cause acute neurovisceral attacks, chronic symptoms, and long-term complications. Accurate biochemical diagnosis, particularly testing for porphobilinogen (PBG) and porphyrins in urine, is crucial for prompt treatment initiation. Increased awareness of AHP and proper diagnostic methods can reduce diagnostic delays and improve patient outcomes.
Acute hepatic porphyria (AHP) is a group of rare, metabolic diseases where patients can experience acute neurovisceral attacks, chronic symptoms, and long-term complications. Diagnostic biochemical testing is widely available and effective, but a substantial time from symptom onset to diagnosis often delays treatment and increases morbidity. A panel of laboratory scientists and clinical AHP specialists collaborated to produce recommendations on how to enhance biochemical diagnosis of AHP in the USA. AHP should be considered in the differential diagnosis of unexplained abdominal pain, the most common symptom, soon after excluding common causes. Measurement of porphobilinogen (PBG) and porphyrins in a random urine sample, with results normalized to creatinine, is recommended as an effective and cost-efficient initial test for AHP. Delta-aminolevulinic acid testing may be included but is not essential. The optimal time to collect a urine sample is during an attack. Substantial PBG elevation confirms an AHP diagnosis and allows for prompt treatment initiation. Additional testing can determine AHP subtype and identify at-risk family members. Increased awareness of AHP and correct diagnostic methods will reduce diagnostic delay and improve patient outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据